Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium is the major intracellular cation; it is essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Dextrose is a monosaccharide that provides calories and may induce osmotic diuresis. Sodium chloride is an electrolyte that maintains fluid and electrolyte balance.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Intravenous infusion at a rate not exceeding 10 mEq/hour and concentration not exceeding 40 mEq/L. Typical adult dose is 10-20 mEq administered over 1-2 hours, repeated as needed based on serum potassium levels. Maximum daily dose is usually 200 mEq.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
The terminal elimination half-life of potassium is not classically defined due to tight homeostatic regulation; however, the biological half-life for exchangeable potassium in the body is approximately 30 days (range 20-40 days) in adults, reflecting slow turnover of intracellular stores. Clinical context: acute shifts from IV infusion are rapidly distributed, with redistribution half-life of ~1-2 hours, but total body elimination depends on renal function.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Renal excretion: >90% of potassium is excreted by the kidneys, primarily via distal tubular secretion. Fecal elimination accounts for <10%, mainly through gastrointestinal secretion. Biliary excretion is negligible.
Category C
Category A/B
Electrolyte
Electrolyte